CereVance Launches Phase 3 Trial of Novel Parkinson's Drug That Skips Dopamine Side Effects
A new non-dopaminergic drug for Parkinson's OFF episodes enters final trial phase with 341 patients and $20M in fresh funding.
Summary
CereVance has completed enrollment for its Phase 3 ARISE trial testing solengepras, a novel daily pill for Parkinson's disease. The trial enrolled 341 patients across the US, Europe, UK, and Australia who experience motor fluctuations — periods when their medication stops working, called OFF time. Unlike standard Parkinson's treatments that target dopamine, solengepras works through a different mechanism called GPR6 inhibition, aiming to reduce these debilitating OFF periods without the side effects typical of dopaminergic drugs. The 12-week study tests two doses against placebo, with results expected by late 2026. The company also closed a $20 million Series C round backed by Google Ventures, Gates Frontier, and several health-focused investors to fund operations through mid-2027.
Detailed Summary
Parkinson's disease affects millions of people worldwide, and one of its most frustrating aspects is the daily experience of OFF periods — windows of time when medication stops controlling symptoms and motor function deteriorates. For patients averaging three or more hours of OFF time per day, this represents a significant quality-of-life and functional health burden. CereVance is now one step closer to offering a new solution.
The company has completed enrollment in its pivotal Phase 3 ARISE trial, bringing in 341 participants across four regions: the United States, Europe, the United Kingdom, and Australia. Participants were randomized to receive solengepras at 75 mg, 150 mg, or placebo once daily over 12 weeks. The primary endpoint is how much the 150 mg dose reduces average daily OFF time compared to placebo — a clinically meaningful and measurable outcome.
What sets solengepras apart is its mechanism. It is a GPR6 inhibitor — a non-dopaminergic approach that sidesteps the receptor system targeted by most existing Parkinson's therapies. Dopaminergic drugs, while effective, carry well-known risks including dyskinesia, hallucinations, and impulse control disorders. A drug that reduces OFF time without triggering these side effects could represent a meaningful advance in Parkinson's management.
To support the trial through its completion, CereVance closed an oversubscribed $20 million Series C round. Investors include Google Ventures, Gates Frontier, Double Point Ventures, and SV Health Investors' Dementia Discovery Fund — a lineup that signals strong institutional confidence in the approach. Proceeds are expected to fund operations through mid-2027, with topline trial data anticipated in Q3 2026.
Caveats remain. Phase 3 results have not yet been reported, and no drug is approved until regulatory review is complete. The trial is also relatively short at 12 weeks, which may not capture longer-term safety or durability of effect. Results from this trial will be the true test of whether solengepras delivers on its early promise.
Key Findings
- Solengepras targets GPR6, not dopamine, potentially avoiding common Parkinson's drug side effects like dyskinesia
- Phase 3 ARISE trial enrolled 341 patients averaging 3+ hours of daily OFF time across 4 countries
- Trial tests 75mg and 150mg daily doses vs placebo over 12 weeks; topline data expected Q3 2026
- $20M Series C backed by Google Ventures and Gates Frontier funds operations through mid-2027
- Primary endpoint measures reduction in average daily OFF time at 12 weeks for the 150mg dose
Methodology
This is a news report summarizing a corporate press release about a clinical trial milestone and funding round. The source, Longevity.Technology, is a reputable longevity-focused outlet, but the information originates from CereVance and has not yet been peer-reviewed. No clinical data has been published; enrollment completion is a procedural milestone.
Study Limitations
No efficacy or safety data has been released yet — trial results are expected in late 2026. The 12-week trial duration may not reflect long-term outcomes. All current information comes from the company and should be verified against published trial data once available.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.